Phillips Medisize, a Molex company specializing in medical technology and pharmaceutical drug delivery manufacturing, has acquired the full footprint of its Chippenham facility in England. The investment strengthens its Global Inhalation Center of Excellence and provides additional capacity for developing and manufacturing inhaled drug delivery products.
The acquisition builds on Phillips Medisize’s purchase of Vectura Group in 2025, which expanded its inhalation technology and pharmaceutical development capabilities.
The Chippenham investment will provide greater long-term control over specialized laboratories, cleanrooms, and manufacturing infrastructure.
Together with the company’s existing Cambridge location, the facility forms an integrated center focused on inhalation drug development and manufacturing.
Phillips Medisize supports pharmaceutical customers developing medicines delivered through the respiratory system.
Its capabilities include dry powder inhalers, nebulizers, formulation development, and combination products involving both medicines and delivery devices.
The company works with small-molecule treatments, biologics, and generic pharmaceutical products.
The newly acquired Chippenham footprint encompasses approximately 634,670 square feet, according to the company’s announcement.
The investment is intended to increase capacity for early-stage research, clinical trial supplies, and commercial manufacturing.
Inhaled medicines can require sophisticated formulation technologies to control how active ingredients are delivered to patients.
Phillips Medisize provides services involving powder and liquid formulations, particle engineering, spray drying, powder blending, analytical testing, and technical transfer.
These capabilities are particularly relevant for treatments involving complex molecules and specialized delivery systems.
The company also supports the development of therapies for conditions such as pulmonary arterial hypertension.
Phillips Medisize expects its inhalation business to experience substantial revenue growth over the next five years.
Management indicated that the business is performing ahead of its growth expectations following the Vectura acquisition.
The Chippenham investment provides additional resources to support that anticipated demand.
The company’s Global Inhalation Center of Excellence combines the Chippenham and Cambridge locations to provide services spanning early development through commercial production.
Pharmaceutical companies increasingly seek contract development and manufacturing organizations capable of handling multiple stages of product development.
Using an integrated partner can help maintain continuity as experimental therapies progress through clinical studies and into commercialization.
Phillips Medisize intends to use its specialized inhalation capabilities and international manufacturing network to address these requirements.
Its broader organization includes 30 locations across North America, Europe, and Asia.
That network encompasses 23 production facilities and seven research and development innovation centers.
Over the past five years, Phillips Medisize has supported more than 200 product launches and 150 drug delivery programs.
The company believes its combination of specialized inhalation expertise and global manufacturing infrastructure creates opportunities to serve pharmaceutical developers with increasingly complex requirements.
The investment also reflects growing demand for outsourced development and manufacturing services.
By securing the full Chippenham facility, Phillips Medisize aims to preserve operational continuity while expanding capabilities needed to support future growth.
The transaction represents another step in integrating the Vectura business and strengthening Phillips Medisize’s position in the inhalation drug delivery market.
KEY QUOTES:
“With our inhalation revenue projected to grow substantially over the next five years, securing this full site ensures we have the dedicated talent, laboratories and cleanroom capacity required to support pharmaceutical companies from early-stage feasibility all the way through commercial scale-up. Since the Vectura acquisition, we are tracking ahead of schedule on our growth model and are confident in our trajectory. This expansion in Chippenham reinforces our momentum and ensures proven technical expertise and manufacturing continuity for our customers worldwide.”
Charlie Schumacher, Vice President Of Inhalation Therapies At Phillips Medisize
“We are deeply grateful for the overwhelming support and positive reception we continue to receive from our customers and the broader respiratory industry following the Vectura acquisition. Our team is absolutely delighted to be where we should be, back at industry conferences and on the podium sharing our latest research. We remain deeply committed to advancing the science in our field to bring more effective inhalation therapies to patients across the world, including those dealing with complex and challenging diseases like Pulmonary Arterial Hypertension (PAH).”
Sandy Munro, Chief Inhalation Scientist At Phillips Medisize
